Sanofi Nigeria-Ghana has reiterated commitment to the use of its brand solution, APROVASC for the management of hypertension in the West African region, reports ITRealms.
The General Manager, Sanofi Nigeria-Ghana, Mr. Abderrahmane Chakibi gre-endorsed this commitment during a demonstration and launch of a new blood pressure control drug, by Sanofi Aventis at Oriental Hotels, Victoria Island in Lagos.
He pointed out that with the introduction of APROVASC, a fixed-dose combination treatment for the management of hypertension, Sanofi committed to healthcare provision through affordable medicines that are tailored to the needs of patients.
"With APROVASC, Sanofi now offers a wide range of treatment options for patients with hypertension. To better support the patients in the management of their disease, Sanofi continues with its access to healthcare ambition in the opening of diabetes and hypertension clinics in partnership with health authorities. The first clinic was inaugurated at the Lagos State University Teaching Hospital (LASUTH) on 29th January 2015," he said.
ITRealms recalls that experts have said that in Nigeria, estimated 28.9 per cent of the population has raised blood pressure while about 82 per cent are not aware of this disease condition.
Just as experts forecasted that by 2030, up to 39.1 million people aged at least 20 years may live with hypertension1 if nothing is done to reverse the trend. Stressing that people with uncontrolled hypertension are exposed to many complications including stroke, heart attack, kidney failure and problems with vision, which can be controlled by adopting healthy diets, lifestyle changes and, in many cases, treatment with medications.
Chakibi underscored the fact that over 90 years’ experience in development and manufacturing, Sanofi is a world leader in delivering quality, innovative solutions to meet the needs of patients. Hence, APROVASC range offers dosage flexibility that affords for individualized treatment.
As said by the GM, by introducing a new antihypertensive treatment, Sanofi demonstrates its commitment to patients through improving access to high quality solutions in the field of hypertension management in Nigeria. APROVASC introduction is another example of Sanofi’s engagement to always provide advanced and innovative treatments in response to patients’ specific needs with the highest efficacy and comfort. This unique combination is the result of years of development, clinical studies and safety proofing” Chakibi said.
He emphasised that delivering innovative treatments and a full portfolio adapted to the needs of patients locally is at the core of what Sanofi, have done for nearly a century.
"But medications alone are not enough. For many years, we have been supporting healthcare professionals in their daily practice through training and other tailored services. Through leveraging APROVASC availability in Nigeria, Sanofi will continue to contribute to making the lives of Nigerian hypertensive patients healthier” Mr. Chakibi said.
L-R: Associate
Professor of Medicine, University of Lagos, Dr. Amam Chinyere Mbakwem;
Deputy Managing Director, Maayoit Healthcare Limited, Dr. Ademola
Aderigbigbe; Chief Medical Director, LASUTH, Prof. Adewale Oke; Business
Unit Head- Ethical Sanofi, Folake Odediran; Head Public Affairs Sanofi
Mr. Oladimeji Agbolade; General Manager, Sanofi Nigeria-Ghana,
Abderrahmane Chakibi; and Head of Medical and
Regulatory, Sanofi Nigeria/Gha
No comments:
Post a Comment